Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17047730 | Parvovirus Vector Production | October 2020 | July 2024 | Allow | 45 | 1 | 0 | No | No |
| 17030911 | HOMOLOGOUS RECOMBINATION DIRECTED GENOME EDITING IN EUKARYOTES | September 2020 | January 2025 | Abandon | 52 | 1 | 0 | No | No |
| 17010349 | TRANSPOSASE COMPOSITIONS FOR REDUCTION OF INSERTION BIAS | September 2020 | September 2024 | Allow | 49 | 2 | 0 | No | No |
| 17010107 | Engineered CRISPR-Cas9 nucleases with Altered PAM Specificity | September 2020 | August 2024 | Allow | 48 | 1 | 0 | No | No |
| 15929386 | SYSTEM AND METHOD FOR TRANSPOSASE-MEDIATED AMPLICON SEQUENCING | April 2020 | January 2025 | Abandon | 57 | 8 | 0 | No | No |
| 16473492 | METHOD FOR EDITING FILAMENTOUS FUNGAL GENOME THROUGH DIRECT INTRODUCTION OF GENOME-EDITING PROTEIN | October 2019 | September 2024 | Allow | 60 | 3 | 1 | No | No |
| 16514748 | GENERATING CELL-FREE DNA LIBRARIES DIRECTLY FROM BLOOD | July 2019 | April 2025 | Abandon | 60 | 3 | 0 | Yes | No |
| 16462337 | Methods For Split-Protein Template Assembly By Proximity-Enhanced Reactivity | May 2019 | December 2024 | Abandon | 60 | 0 | 1 | No | No |
| 15270998 | METHODS FOR PREDICTING RESPONSE OF TRIPLE-NEGATIVE BREAST CANCER TO THERAPY | September 2016 | August 2019 | Allow | 35 | 2 | 0 | Yes | Yes |
| 14992431 | REPAIR AND REGENERATION OF OCULAR TISSUE USING POSTPARTUM-DERIVED CELLS | January 2016 | January 2019 | Allow | 36 | 2 | 1 | No | No |
| 13341805 | METHYLATION ANALYSIS TO DETERMINE THE PRESENCE OF CANCER CELLS | December 2011 | March 2015 | Allow | 38 | 2 | 1 | Yes | No |
| 13058613 | Screening assays for compounds that modulate programmed ribosomal frameshifting | February 2011 | September 2014 | Allow | 43 | 2 | 1 | Yes | No |
| 13058653 | METHODS FOR TREATING SPINAL MUSCULAR ATROPHY | February 2011 | November 2014 | Allow | 45 | 2 | 1 | Yes | No |
| 12522075 | IN VIVO GENOME-WIDE MUTAGENESIS | February 2010 | May 2013 | Allow | 47 | 2 | 0 | No | No |
| 12490195 | METHOD FOR THE DIAGNOSIS OF SCHIZOPHRENIA | June 2009 | December 2010 | Allow | 18 | 1 | 0 | Yes | No |
| 12400955 | HYPOXIA INDUCING FACTORS AND USES THEREOF FOR INDUCING ANGIOGENESIS AND IMPROVING MUSCULAR FUNCTIONS | March 2009 | September 2011 | Allow | 30 | 1 | 1 | Yes | No |
| 12363650 | TRANSCRIPTION FACTOR HAVING ZINC FINGER DOMAINS | January 2009 | June 2011 | Allow | 29 | 1 | 1 | Yes | No |
| 12196164 | BLOCKING SPORULATION BY INHIBITING SPOIIE | August 2008 | October 2011 | Allow | 38 | 2 | 1 | Yes | No |
| 12278903 | PROCESS AND CULTURING UNIT FOR CULTURING BIOLOGICAL CELLS | August 2008 | November 2014 | Allow | 60 | 3 | 1 | Yes | No |
| 12116307 | METHOD FOR DIAGNOSING OVERACTIVE BLADDER | May 2008 | January 2012 | Allow | 45 | 2 | 0 | Yes | Yes |
| 11969799 | ESTABLISHED MARUCA VITRATA CELL LINE | January 2008 | July 2011 | Allow | 43 | 2 | 0 | Yes | No |
| 11827396 | RECOMBINANT C140 RECEPTOR, IT'S AGONISTS AND ANTAGONISTS, AND NUCLEIC ACIDS ENCODING THE RECEPTOR | July 2007 | August 2010 | Allow | 37 | 3 | 0 | No | No |
| 10575127 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS INVOLVING ABNORMAL ANGIOGENESIS | June 2007 | August 2010 | Allow | 52 | 2 | 1 | Yes | No |
| 10578203 | Prion-Like Form of Cpeb and Related Compositions and Methods | March 2007 | October 2014 | Allow | 60 | 3 | 1 | Yes | No |
| 11604400 | RET FINGER PROTEIN 2 (RFP2) PROMOTER | November 2006 | March 2011 | Allow | 52 | 3 | 0 | Yes | No |
| 11438933 | MODULATION OF HEDGEHOG-MEDIATED SIGNALING PATHWAY | May 2006 | June 2010 | Allow | 49 | 3 | 1 | Yes | No |
| 11330363 | MIDECAMYCIN BIOSYNTHESIS GENES | January 2006 | April 2010 | Allow | 51 | 3 | 1 | No | No |
| 11011349 | AEQUORIN AS A GROWTH MARKER IN YEAST | December 2004 | July 2009 | Allow | 55 | 5 | 0 | No | Yes |
| 10977087 | HX2004-6 POLYPEPTIDE EXPRESSED IN CANCEROUS CELLS | October 2004 | August 2010 | Allow | 60 | 2 | 3 | Yes | No |
| 10506192 | COLD SHOCK INDUCIBLE EXPRESSION AND PRODUCTION OF HETEROLOGOUS POLYPEPTIDES | September 2004 | June 2009 | Allow | 57 | 3 | 1 | No | No |
| 10505328 | GENOME MINIMIZATION BY TN5-COUPLED CRE/LOXP EXCISION SYSTEM | August 2004 | February 2010 | Allow | 60 | 1 | 0 | Yes | No |
| 10483241 | ONCOSUPPORESSIVE GENE | July 2004 | November 2006 | Allow | 34 | 1 | 1 | No | No |
| 10876787 | BIOMARKERS FOR WOUND HEALING | June 2004 | June 2011 | Allow | 60 | 8 | 1 | Yes | Yes |
| 10842142 | PROTEIN KINASE C ZETA AS A DRUG TARGET FOR ARTHRITIS AND OTHER INFLAMMATORY DISEASES | May 2004 | August 2009 | Allow | 60 | 6 | 1 | Yes | No |
| 10493393 | HUMAN AND MAMMALIAN STEM CELL-DERIVED NEURON SURVIVAL FACTORS | April 2004 | April 2007 | Allow | 36 | 3 | 1 | No | No |
| 10827133 | DESTABILIZED BIOLUMINESCENT PROTEINS | April 2004 | April 2007 | Allow | 36 | 4 | 0 | No | No |
| 10479546 | DETECTION OF MECT1-MAML2 FUSION PRODUCTS | March 2004 | December 2006 | Allow | 37 | 2 | 1 | No | No |
| 10786461 | IN VITRO MASS PRODUCTION OF HUMAN ERYTHROID CELLS FROM THE BLOOD OF NORMAL DONORS AND THALASSEMIC PATIENTS | February 2004 | May 2005 | Allow | 15 | 1 | 0 | No | No |
| 10767630 | METHODS AND COMPOSITIONS FOR HUMAN BLADDER EPITHELIAL CELL CULTURE | January 2004 | September 2006 | Allow | 31 | 3 | 0 | No | No |
| 10764581 | METHODS OF RNA AND PROTEIN SYNTHESIS | January 2004 | August 2006 | Allow | 30 | 2 | 1 | No | No |
| 10669861 | ZINC FINGER TRANSCRIPTION FACTOR DIFFERENTIATION PROTEINS | September 2003 | December 2008 | Allow | 60 | 5 | 1 | Yes | No |
| 10661242 | DIAGNOSIS OF MILD OSTEOARTHRITIS BY DETERMINATION OF TNFAIP6 AND TGFBI RNA LEVELS | September 2003 | December 2007 | Allow | 51 | 2 | 1 | No | No |
| 10645250 | NUCLEIC ACID MOLECULES ENCODING NRC INTERACTING FACTOR-1 (NIF-1) | August 2003 | September 2007 | Allow | 49 | 2 | 1 | No | Yes |
| 10623914 | PROBES FOR CHONDROGENESIS | July 2003 | November 2007 | Allow | 51 | 2 | 1 | No | No |
| 10447834 | APPARATUS AND METHOD FOR REINFORCING CONCRETE USING REBAR SUPPORTS | May 2003 | January 2005 | Allow | 19 | 2 | 0 | No | No |
| 10438279 | CULTURABLE MITOCHONDRIAL CELLS WITH NO NUCLEUS, SHOWING MITOCHONDRIAL ACTIVITY | May 2003 | February 2006 | Allow | 33 | 2 | 1 | No | No |
| 10428977 | IN VITRO MUTAGENESIS, PHENOTYPING, AND GENE MAPPING | May 2003 | December 2006 | Allow | 43 | 2 | 1 | No | No |
| 10415489 | NOVEL CLOCK GENE PROMOTER | April 2003 | June 2005 | Allow | 25 | 2 | 0 | No | No |
| 10400348 | IDENTIFYING CALCINEURIN ACTIVATORS FOR TREATMENT OF SCHIZOPHRENIA | March 2003 | December 2010 | Allow | 60 | 3 | 1 | Yes | No |
| 10389821 | THERMOANAEROBACTER BROCKII ALCOHOL DEHYDROGENASE PROMOTER FOR EXPRESSION OF HETEROLOGOUS PROTEINS | March 2003 | April 2007 | Allow | 49 | 4 | 0 | No | No |
| 10168365 | POLYNUCLEOTIDES ENCODING STEM CELL GROWTH FACTOR-LIKE POLYPEPTIDES | February 2003 | August 2007 | Allow | 60 | 4 | 1 | No | No |
| 10319316 | COMPOSITIONS FOR IMPORTING BIOLOGICALLY ACTIVE MOLECULES INTO CELLS | December 2002 | August 2012 | Allow | 60 | 9 | 1 | Yes | Yes |
| 10301498 | DETECTION METHODS BASED ON HR23 PROTEIN BINDING MOLECULES | November 2002 | June 2010 | Allow | 60 | 4 | 1 | Yes | No |
| 10282617 | NOVEL ZINC FINGER PROTEINS | October 2002 | June 2007 | Allow | 56 | 2 | 1 | No | No |
| 10242535 | DIAGNOSIS OF OSTEOARTHRITIS BY DETERMINATION OF ASPORIN RNA LEVELS | September 2002 | July 2010 | Allow | 60 | 3 | 1 | No | Yes |
| 10229148 | MIDECAMYCIN BIOSYNTHETIC GENES | August 2002 | October 2005 | Allow | 38 | 2 | 1 | No | No |
| 10228931 | ANIMAL MODEL SYSTEM FOR PHTODAMAGE, PHOTOAGING AND SKIN WOUNDING | August 2002 | January 2005 | Allow | 29 | 1 | 0 | No | No |
| 10223837 | TRANSGENIC MICE OVEREXPRESSING ASPARTYL PROTEASE 2 (ASP2) | August 2002 | March 2005 | Allow | 31 | 1 | 1 | No | No |
| 10204200 | CELL FUSION ASSAYS USING FLUORESCENCE RESONANCE ENERGY TRANSFER | August 2002 | June 2005 | Allow | 34 | 2 | 0 | No | Yes |
| 10089543 | ISOLATION AND CHARACTERIZATION OF A FIBER-SPECIFIC BETA-TUBULIN PROMOTER FROM COTTON | August 2002 | September 2005 | Allow | 41 | 1 | 0 | No | No |
| 10200879 | PEPTIDE-ENHANCED TRANSFECTIONS | July 2002 | June 2011 | Allow | 60 | 7 | 1 | Yes | Yes |
| 10186732 | HYDROPHOBE BIOMOLECULAR STRUCTURE | July 2002 | March 2005 | Allow | 33 | 1 | 1 | No | No |
| 10130739 | PHOSPHORUS-CONTAINING DENDRIMERS AS TRANSFECTION AGENTS | July 2002 | August 2005 | Allow | 39 | 2 | 0 | No | No |
| 10177478 | CHIMERIC HISTONE ACETYLTRANSFERASE POLYPEPTIDES | June 2002 | April 2007 | Allow | 58 | 3 | 2 | No | No |
| 10130872 | TRANSCRIPTION FACTOR POLYPEPTIDE THAT REGULATES CHONDROMODULIN-I EXPRESSION | May 2002 | March 2007 | Allow | 58 | 3 | 1 | No | No |
| 10150759 | METHOD OF IDENTIFYING SUBSTANCES USEFUL FOR PROMOTING RESISTANCE TO CELL STRESS | May 2002 | September 2007 | Allow | 60 | 4 | 1 | No | No |
| 10143293 | INHIBITORS OF RECEPTOR ACTIVATOR OF NF-KAPPAB AND USES THEREOF | May 2002 | October 2004 | Allow | 30 | 1 | 1 | No | No |
| 10120013 | RIBONUCLEASE RESISTANT RNA PREPARATION AND UTILIZATION | April 2002 | August 2005 | Allow | 41 | 3 | 1 | No | No |
| 10104137 | ALGORITHM FOR SELECTING AUDIO CONTENT | March 2002 | September 2005 | Allow | 42 | 2 | 0 | Yes | No |
| 09971536 | LACTOBACILLUS RHAMNOSUS POLYNUCLEOTIDES, POLYPEPTIDES AND METHODS FOR USING THEM | October 2001 | June 2005 | Allow | 45 | 0 | 1 | No | No |
| 09830669 | CELLS AND METHOD FOR PRODUCING PROTEINS COMPRISING AN UNCONVENTIONAL AMINO ACID | April 2001 | January 2010 | Allow | 60 | 10 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner DUNSTON, JENNIFER ANN.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 40.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner DUNSTON, JENNIFER ANN works in Art Unit 1637 and has examined 71 patent applications in our dataset. With an allowance rate of 94.4%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 47 months.
Examiner DUNSTON, JENNIFER ANN's allowance rate of 94.4% places them in the 82% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.
On average, applications examined by DUNSTON, JENNIFER ANN receive 2.70 office actions before reaching final disposition. This places the examiner in the 75% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by DUNSTON, JENNIFER ANN is 47 months. This places the examiner in the 10% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +3.1% benefit to allowance rate for applications examined by DUNSTON, JENNIFER ANN. This interview benefit is in the 26% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.
When applicants file an RCE with this examiner, 25.0% of applications are subsequently allowed. This success rate is in the 40% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 52.8% of cases where such amendments are filed. This entry rate is in the 80% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 93% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 86% percentile among all examiners. Of these withdrawals, 88.9% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 64.7% are granted (fully or in part). This grant rate is in the 68% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 35.2% of allowed cases (in the 100% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 3.0% of allowed cases (in the 75% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.